Mesenchymal stem cells and autoimmune diseases
Mesenchymal stem cells and autoimmune diseases
复制标题
DOI：
10.1016/j.beha.2011.01.002
复制
发表时间：
2011-03-01
影响因子：
2.1
通讯作者：
Krampera, Mauro
中科院分区：
文献类型：
--
作者：
Dazzi, Francesco;Krampera, Mauro
间充质干细胞（MSC）的免疫抑制特性为自身免疫性疾病提供了一种潜在的有吸引力的治疗方式。MSC在体外抑制几乎所有类型的免疫应答，并在几种自身免疫实验模型中预防疾病的诱导。然而，人类疾病的发病机制涉及的过程更为复杂，在疾病诱发之前无法进行治疗。在自身免疫性疾病中，持续的抗原刺激将内源性MSC募集到病变部位，从而导致纤维化演变。因此，向慢性炎性病症施用MSC可能不是期望的。事实上。MSC不是组成性免疫抑制的，但需要由急性期炎症分子如IFN γ和TNF-α或toll样受体（TLR）配体提供的“许可”步骤。相反，不同的细胞因子和/或选择性TLR的刺激使MSC变得具有免疫刺激性。因此，解剖自身免疫性疾病中的炎症环境将确定适合成功MSC治疗的最佳条件。皇冠版权所有（C）2011由爱思唯尔有限公司出版。保留所有权利。
Mesenchymal stem cell (MSC) immunosuppressive properties offer a potentially attractive therapeutic modality for autoimmune diseases. MSC inhibit virtually all types of immune responses in vitro and prevent the induction of disease in several experimental models of autoimmunity. However, the processes involved in the pathogenesis of human diseases are more complicated and treatment cannot be administered before disease induction. In autoimmune diseases persistent antigenic stimulation recruits endogenous MSC to the site of lesion that contribute to the fibrotic evolution. Therefore, administering MSC to a chronic inflammatory disorder may not be desirable. In fact. MSC are not constitutively immunosuppressive but require a 'licensing' step provided by molecules of acute phase inflammation, like IFN gamma and TNF-alpha, or toll-like receptor (TLR) ligands. Conversely, different cytokines and/or the stimulation of selective TLR make MSC to become immunostimulatory. Therefore, dissecting the inflammatory environment in autoimmune diseases will identify the best conditions amenable to successful MSC therapy. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.